|1.||Salgia, Ravi: 35 articles (06/2015 - 01/2003)|
|2.||Wang, Ming-Hai: 18 articles (01/2015 - 09/2002)|
|3.||Waltz, Susan E: 18 articles (08/2014 - 01/2002)|
|4.||Heinrich, Michael C: 17 articles (03/2010 - 05/2002)|
|5.||Christensen, James G: 16 articles (11/2014 - 09/2003)|
|6.||Earp, H Shelton: 14 articles (09/2015 - 02/2003)|
|7.||Yarden, Yosef: 13 articles (01/2015 - 05/2002)|
|8.||Zhou, Yong-Qing: 13 articles (12/2014 - 09/2002)|
|9.||Berdel, Wolfgang E: 13 articles (01/2014 - 04/2003)|
|10.||Graham, Douglas K: 12 articles (09/2015 - 01/2008)|
05/01/2014 - "Herein we disclose the use of this approach for the discovery of dual FMS-like receptor tyrosine kinase-3 (FLT3)-Aurora A inhibitors against cancer. "
01/01/2014 - "Strategies to overcome drug resistance of receptor tyrosine kinaseaddicted cancer cells."
10/15/2010 - "Analysis of Met receptor tyrosine phosphorylation, proliferation, apoptosis and blood vessels in the tumor tissues indicated that the inhibitory effect of NK4 expression might be primarily caused by the inhibition of tumor angiogenesis. "
12/29/2009 - "Embryonic stem cell tumor model reveals role of vascular endothelial receptor tyrosine phosphatase in regulating Tie2 pathway in tumor angiogenesis."
03/01/2006 - "A non-receptor tyrosine phosphatase, PTPN4, was found to be expressed in a tumor-tissue profile with only low frequency. "
|2.||Renal Cell Carcinoma (Grawitz Tumor)
01/01/2015 - "High expression of the receptor tyrosine kinase Axl is associated with poor prognosis in patients with Renal Cell Carcinoma (RCC), the most common malignancy of the kidney. "
07/01/2014 - "Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance."
01/01/2014 - "Decreased expression of receptor tyrosine kinase of EphB1 protein in renal cell carcinomas."
06/01/2012 - "There have been recent improvements in the treatment for metastatic renal cell carcinoma (RCC) with receptor tyrosine kinase (RTK) inhibitors being one of newer treatment options. "
06/01/2012 - "Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration."
|3.||Breast Neoplasms (Breast Cancer)
01/01/2007 - "The anti-tyrosine receptor drugs are among the most developed, some of them having already been approved by the FDA and the EMEA for breast cancer, colorectal, lung GIST and renal cancer treatment. "
12/01/2013 - "To perform a systematic review and meta-analysis of randomized controlled trials to determine the efficacy and toxicity of approved vascular epithelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) in advanced breast cancer. "
12/01/2013 - "The role of vascular epithelial growth factor receptor-tyrosine kinase inhibitors in the treatment of advanced breast cancer: a meta-analysis of 12 randomized controlled trials."
03/15/2010 - "These studies identify a link between the Met receptor tyrosine kinase, epithelial mesenchymal transition, and basal breast cancer. "
08/01/2015 - "Twenty years have passed since the non-receptor tyrosine kinase, Breast tumor kinase (BRK) was cloned. "
|4.||Neoplasm Metastasis (Metastasis)
11/10/2015 - "Therefore, our results demonstrate that besides the canonical role of EGFR as a receptor tyrosine, the mitochondrial translocation of EGFR may enhance cancer invasion and metastasis through regulating mitochondria dynamics. "
10/01/2010 - "The receptor tyrosine kinase AXL is thought to play a role in metastasis; however, the therapeutic efficacy of an AXL-targeting agent remains largely untested in metastatic disease. "
09/01/2002 - "New agents targeting aberrant receptor tyrosine kinases, the Ras oncoprotein, mediators of metastases and angiogenesis, and the tumor suppressor gene p53 have, among other agents, shown promise in preclinical studies. "
06/01/2015 - "The present review describes how protein trafficking facilitates invasion and metastasis of CRC cells and focuses on receptor tyrosine kinases (RTKs) endocytic transport, providing thoughts for surpassing RTKs-centered mechanisms of resistance. "
01/01/2015 - "Concurrently, the receptor tyrosine kinase c-kit is highly expressed in skeletal metastases of PCa patients and induced in PCa cells placed into the bone microenvironment in experimental models. "
01/01/2010 - "Recent studies of the TAM (Tyro3, Axl and MerTK) family of receptor tyrosine kinases may lead to a better understanding of the fundamental control system responsible for the clearance of apoptotic cells and the regulation of inflammation. "
09/24/2015 - "The non-receptor tyrosine kinase Abl is linked to neuro-inflammation in AD. "
01/01/2015 - "The TAM receptor tyrosine kinases (RTKs)-TYRO3, AXL, and MERTK-together with their cognate agonists GAS6 and PROS1 play an essential role in the resolution of inflammation. "
04/17/2014 - "TAM receptors (Tyro3, Axl, and Mer) belong to a family of receptor tyrosine kinases that have important effects on hemostasis and inflammation. "
10/15/2013 - "RON receptor tyrosine kinase, a negative regulator of inflammation, is decreased during simian immunodeficiency virus-associated central nervous system disease."
|4.||Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
|5.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|6.||sorafenib (BAY 43-9006)
|7.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|10.||4- ((4- Fluoro- 2- methyl- 1H- indol- 5- yl)oxy)- 6- methoxy- 7- (3- (pyrrolidin- 1- yl)propoxy)quinazoline (AZD2171)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Molecular Targeted Therapy